Search for Clinical Trial Results
Paramyxoviridae Infections - 25 Studies Found
Status | Study |
Completed |
Study Name: Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children Condition: Healthy Date: 2006-06-27 Interventions:
|
Withdrawn |
Study Name: DAS181 in Patients With Parainfluenza Condition: Parainfluenza Infection Date: 2011-09-24 Interventions:
|
Completed |
Study Name: Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine Condition:
Date: 2008-03-05 Interventions:
|
Recruiting |
Study Name: A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers Condition:
Date: 2005-09-12 Interventions: Biological: Sendai virus vaccine Enders strain; a live, unmodified intranasally administered Sendai viru |
Completed |
Study Name: Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults Condition: Hemorrhagic Fever, Ebola Date: 2015-09-29 Interventions: Biological: HPIV3-EbovZ GP Vaccine Administered intranasally by a VaxINator device |
Completed |
Study Name: Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study Condition: Respiratory Syncytial Virus (RSV) Infection Date: 2016-03-21 Interventions:
|
Recruiting |
Study Name: Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age Condition: Respiratory Syncytial Virus Infections Date: 2017-03-23 Interventions:
|
Recruiting |
Study Name: Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age Condition: Respiratory Syncytial Virus Infections Date: 2017-03-28 Interventions:
|
Active, not recruiting |
Study Name: A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women Condition: Respiratory Syncytial Virus Infections Date: 2016-11-03 Interventions:
|
Active, not recruiting |
Study Name: Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age Condition: Respiratory Syncytial Virus Infections Date: 2016-10-31 Interventions:
|